The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARC-20: A phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors.
 
Toni K. Choueiri
Stock and Other Ownership Interests - Curesponse; Osel; Pionyr; Precede Bio; Tempest Therapeutics
Honoraria - Honoraria and Advisory/Consultancy are same
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Benjamin Garmezy
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Exelixis (Inst); Genentech (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kinnate Biopharma (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen (Inst); AVEO (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Sanofi (Inst)
 
Elaine Paterson
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences
Travel, Accommodations, Expenses - Arcus Biosciences
 
Mohammad Ghasemi
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences
 
Tzuling Cheng
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences
 
Paul G. Foster
Employment - Arcus Biosciences
Stock and Other Ownership Interests - Arcus Biosciences
 
Ralph J. Hauke
Stock and Other Ownership Interests - Aethlon
Honoraria - Best Doctors, Inc
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Tizona Therapeutics, Inc. (Inst); US Oncology (Inst)
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)